JPMorgan Upgrades Baidu: Cloud and AI to Drive Growth
JPMorgan upgrades Baidu to Overweight, citing strong growth potential in cloud and AI, with a new price target of $188.
Already have an account? Sign in.
JPMorgan upgrades Baidu to Overweight, citing strong growth potential in cloud and AI, with a new price target of $188.
JPMorgan bullish on BILI: AI investments fuel engagement, 25%+ ad revenue growth. "Solid profit compounder" with strong upside potential.
Pre-revenue Oklo reports wider-than-expected 2025 loss of $0.72/share. Stock struggles persist despite regulatory progress focus.
Myriad Genetics' MyChoice CDx gains FDA approval as the only CDx to identify HRD-positive patients for Zejula maintenance in advanced ovarian cancer, boosting precision therapy.